CAHR Abstracts 2002

Return to Main Menu

Search CAHR Abstracts

BASIC SCIENCES / SCIENCES FONDAMENTALES
ORAL PRESENTATIONS / PRÉSENTATIONS ORALES

REGULATION OF INFECTION/REPLICATION

[115] EXPRESSION OF THE HUMAN NEUROENDOCRINE RECEPTOR VPAC1 IS NECESSARY AND SUFFICIENT FOR HIV-1 INFECTION OF CHINESE HAMSTER OVARY CELLS
Linda JE Valenta, Darinka Sakac, Xue-Zhong Ma, Donald R Branch
Institute of Medical Science and Department of Medicine, University of Toronto; the Canadian Blood Services, Toronto, Ontario

[116] A POLYMORPHISM OF THE CD4 MOLECULE IS ASSOCIATED WITH INCREASED RISK OF HIV INFECTION
Jonathan Bellas, Stephen Wayne, T Blake Ball, Joanne E Embree, Keith R Fowke
Laboratory of Viral Immunology, Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba

[117] THE INFLUENCE OF LONG TERMINAL REPEAT SEQUENCE VARIATION ON VIRAL LOAD IN DRUG NAIVE PATIENTS
Lindsay Quayle1, Zhaoxia Chen2, Sherie Savoy3, Fiona M Smaill3, Benoit Barbeau4, John E Kim2, Karen FT Copeland1
1Ottawa Health Research Institute, Ottawa, Ontario; 2National HIV Reference Services Laboratory, Health Canada, Ottawa, Ontario; 3McMaster University, Health Sciences Centre, Hamilton, Ontario; 4Centre de Recherche du CHUL, Sainte-Foy, Quebec

[118] DIRECT MEASUREMENT OF REDUCED REPLICATIVE FITNESS OF DRUG RESISTANT HIV IN PATIENTS STOPPING ANTIRETROVIRAL THERAPY
P Richard Harrigan, Christopher Alexander, M Whaley, MV O’Shaughnessy, JSG Montaner
BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia

[119] SUPPRESSION OF IL-12 p40 TRANSCRIPTION BY ACUTE HIV INFECTION: DISRUPTION OF NUCLEAR FACTOR BINDING AND INHIBITION OF MAP KINASE ACTIVATION
Kelley A Chambers, Jonathan B Angel
Ottawa Health Research Institute, Ottawa, Ontario

[120] IDENTIFICATION OF A POTENT INHIBITOR OF HIV-1 Rev FUNCTION
Jodi Bubenik, Alan Cochrane
Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario

[121] MODULATION OF CYTOCHROME P450 3A4 AND P-GLYCOPROTEIN BY GOLDENSEAL AND MILK THISTLE PRODUCTS
JW Budzinski1, JT Arnason1, V Trudeau1, A Krantis2, M Panahi2, BC Foster2,3
1Ottawa-Carleton Institute of Biology; 2Centre for Research in Biopharmaceuticals, University of Ottawa; 3Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, Ontario